BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study

HACKENSACK, N.J., PETACH TIKVA, Israel and DUARTE, Calif., May 16, 2017 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell manufacturing team at City of Hope’s Center for Biomedicine and Genetics to produce clinical supplies of NurOwn® adult stem cells for the company’s randomized, double-blind, multi-dose Phase 3 clinical study in patients with Amyotrophic Lateral Sclerosis (ALS).  City of Hope will be the clinical supplier for all U.S. medical centers participating in the Phase 3 trial.